IN2014KN02935A - - Google Patents
Info
- Publication number
- IN2014KN02935A IN2014KN02935A IN2935KON2014A IN2014KN02935A IN 2014KN02935 A IN2014KN02935 A IN 2014KN02935A IN 2935KON2014 A IN2935KON2014 A IN 2935KON2014A IN 2014KN02935 A IN2014KN02935 A IN 2014KN02935A
- Authority
- IN
- India
- Prior art keywords
- 6alkyl
- hydrogen
- 6alkoxy
- proviso
- hydroxy
- Prior art date
Links
- 229910052739 hydrogen Inorganic materials 0.000 abstract 11
- 239000001257 hydrogen Substances 0.000 abstract 11
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 11
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 9
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 101100406797 Arabidopsis thaliana PAD4 gene Proteins 0.000 abstract 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 201000003883 Cystic fibrosis Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 101150094373 Padi4 gene Proteins 0.000 abstract 1
- 102100035731 Protein-arginine deiminase type-4 Human genes 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 206010047115 Vasculitis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 206010025135 lupus erythematosus Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Compounds of formula (I) wherein; R1 is hydrogen or C1-6alkyl; R2 is hydrogen, C1-6alkyl, perhalomethylC0-5alkyl-O-, or C1-6alkoxy; R3 is hydrogen, C1-6alkyl, or C1-6alkoxyC1-6alkyl; R4 is hydrogen, C1-6alkyl, perhalomethylC1-6alkyl; or unsubstituted C3-6cycloalkylC1-6alkyl; A is C-R5 or N; B is C-R6 or N; D is C-R7 or N; with the proviso that at least one of A, B, and D, is N; R5 is hydrogen or C1-6alkyl; R6 is hydrogen or C1-6alkyl; R7 is hydrogen, C1-6alkyl, C1-6alkoxy, or hydroxy; R8 is hydrogen or C1-6alkyl, with the proviso that one of R4 and R8 is hydrogen; R9 is hydrogen or hydroxy; R10 is hydrogen or C1-6alkyl; and salts thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, and psoriasis.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2012/064649 WO2014015905A1 (en) | 2012-07-26 | 2012-07-26 | 2 - (azaindol- 2 -yl) benz imidazoles as pad4 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014KN02935A true IN2014KN02935A (en) | 2015-05-08 |
Family
ID=49996626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2935KON2014 IN2014KN02935A (en) | 2012-07-26 | 2012-07-26 |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US9127003B2 (en) |
| EP (1) | EP2877467B1 (en) |
| JP (1) | JP6063567B2 (en) |
| KR (1) | KR101916443B1 (en) |
| CN (1) | CN104470919B (en) |
| AU (1) | AU2012386257B2 (en) |
| BR (1) | BR112015001545B1 (en) |
| CA (1) | CA2879341C (en) |
| CY (1) | CY1118524T1 (en) |
| DK (1) | DK2877467T3 (en) |
| ES (1) | ES2609126T3 (en) |
| HR (1) | HRP20161530T1 (en) |
| HU (1) | HUE033294T2 (en) |
| IN (1) | IN2014KN02935A (en) |
| LT (1) | LT2877467T (en) |
| PL (1) | PL2877467T3 (en) |
| PT (1) | PT2877467T (en) |
| RS (1) | RS55684B1 (en) |
| RU (1) | RU2611010C2 (en) |
| SI (1) | SI2877467T1 (en) |
| SM (2) | SMT201700052T1 (en) |
| WO (1) | WO2014015905A1 (en) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2986199C (en) * | 2015-05-21 | 2023-07-18 | Glaxosmithkline Intellectual Property Development Limited | Benzoimidazole derivatives as pad4 inhibitors |
| AR107030A1 (en) * | 2015-12-09 | 2018-03-14 | Padlock Therapeutics Inc | AZA-BENCIMIDAZOL INHIBITORS OF PAD4 |
| AR107032A1 (en) * | 2015-12-09 | 2018-03-14 | Padlock Therapeutics Inc | PAD4 BICYCLIC INHIBITORS |
| AR107694A1 (en) | 2016-02-23 | 2018-05-23 | Padlock Therapeutics Inc | PAD4 INHIBITORY HETEROARILOS |
| CN107188867A (en) * | 2016-03-14 | 2017-09-22 | 中国科学院天津工业生物技术研究所 | The inhibitor of arginine deiminase 4 |
| WO2018022897A1 (en) * | 2016-07-27 | 2018-02-01 | Padlock Therapeutics, Inc. | Covalent inhibitors of pad4 |
| CN110248934B (en) * | 2016-09-12 | 2022-05-24 | 帕德罗科治疗公司 | Heteroaryl PAD4 inhibitors |
| WO2018102262A1 (en) * | 2016-12-02 | 2018-06-07 | University Of Massachusetts | Inhibitors of protein arginine deiminases (pads) and methods of preparation and use thereof |
| CN108689946B (en) * | 2017-04-12 | 2022-10-18 | 中国科学院上海药物研究所 | 2-substituted sulfenyl acetamide compound and preparation method and application thereof |
| SG11202002032SA (en) * | 2017-09-22 | 2020-04-29 | Jubilant Epipad LLC | Heterocyclic compounds as pad inhibitors |
| CA3076476A1 (en) * | 2017-10-18 | 2019-04-25 | Jubilant Epipad LLC | Imidazo-pyridine compounds as pad inhibitors |
| BR112020008851A2 (en) | 2017-11-06 | 2020-10-20 | Jubilant Prodel LLC | compound of formula i, process for preparing compounds of formula i, pharmaceutical composition, method for treating and / or preventing various diseases, use, method for treating cancer, method of treating cancer and method for treating and / or prevention of cancer and infectious diseases |
| PL3704120T3 (en) | 2017-11-24 | 2024-09-16 | Jubilant Episcribe Llc | Heterocyclic compounds as prmt5 inhibitors |
| WO2019161803A1 (en) | 2018-02-26 | 2019-08-29 | 南京药捷安康生物科技有限公司 | Peptidylarginine deiminase inhibitor and use thereof |
| SG11202008950PA (en) | 2018-03-13 | 2020-10-29 | Jubilant Prodel LLC | Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation |
| US12448374B2 (en) | 2018-06-07 | 2025-10-21 | Disarm Therapeutics, Inc. | Inhibitors of SARM1 |
| JP7447080B2 (en) | 2018-08-08 | 2024-03-11 | ブリストル－マイヤーズ スクイブ カンパニー | Substituted thienopyrroles as PAD4 inhibitors |
| US20220402950A1 (en) * | 2018-08-08 | 2022-12-22 | Bristol-Myers Squibb Company | Substituted benzimidazoles as pad4 inhibitors |
| EP3833439B1 (en) * | 2018-08-08 | 2023-07-12 | Bristol-Myers Squibb Company | Benzimidazole inhibitors of pad enzymes |
| AU2019319835A1 (en) * | 2018-08-08 | 2021-03-25 | Bristol-Myers Squibb Company | Indole and azaindole inhibitors of PAD enzymes |
| CN109369513B (en) * | 2018-11-20 | 2020-08-25 | 都创(上海)医药科技有限公司 | Preparation method of FBDD common molecular fragment |
| CN113164508B (en) | 2018-12-19 | 2025-07-08 | 达萨玛治疗公司 | SARM1 inhibitors in combination with neuroprotective agents |
| EP3994128A4 (en) * | 2019-07-03 | 2022-12-07 | University of Massachusetts | PROTEIN ARGININE DEIMINASE (PAD) INHIBITORS AND METHODS OF PREPARATION AND USE THEREOF |
| WO2021057910A1 (en) * | 2019-09-27 | 2021-04-01 | 南京药捷安康生物科技有限公司 | Peptidylarginine deiminase inhibitor and use thereof |
| KR20220137694A (en) | 2020-02-06 | 2022-10-12 | 브리스톨-마이어스 스큅 컴퍼니 | Macrocyclic PAD4 inhibitors useful as immunosuppressants |
| TW202140477A (en) * | 2020-02-12 | 2021-11-01 | 美商必治妥美雅史谷比公司 | Heterocyclic pad4 inhibitors |
| CN111265526B (en) * | 2020-04-09 | 2021-03-19 | 黑龙江中医药大学 | Medicine for treating gastric cancer and preparation method thereof |
| CN115551862B (en) | 2020-04-30 | 2024-04-12 | 吉利德科学公司 | Macrocyclic inhibitors of peptidyl arginine deiminase |
| CA3192236A1 (en) | 2020-09-10 | 2022-03-17 | Tony Lahoutte | Antibody fragment against fap |
| US20230365589A1 (en) | 2020-09-18 | 2023-11-16 | Sumitomo Pharma Co., Ltd. | Novel amine derivatives |
| EP4267562A1 (en) | 2020-12-22 | 2023-11-01 | Gilead Sciences, Inc. | Inhibitors of peptidylarginine deiminases |
| EP4267587A2 (en) | 2020-12-22 | 2023-11-01 | Gilead Sciences, Inc. | Inhibitors of peptidylarginine deiminases |
| WO2023083365A1 (en) | 2021-11-15 | 2023-05-19 | Qilu Regor Therapeutics Inc. | Pad4 inhibitors and use thereof |
| WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
| AU2023264245A1 (en) | 2022-05-02 | 2024-12-19 | Precirix N.V. | Pre-targeting |
| KR20250027599A (en) * | 2022-05-26 | 2025-02-26 | 셀진 코포레이션 | Heterocyclic PAD4 inhibitors |
| JP2025537627A (en) * | 2022-11-24 | 2025-11-19 | ヘリオス ファミン バイオファーマ カンパニー リミテッド | Selenium-containing heterocyclic compounds and uses thereof |
| KR20260041867A (en) | 2023-07-21 | 2026-03-27 | 브리스톨-마이어스 스큅 컴퍼니 | Method for evaluating the citrullination and activity of PAD4 modifiers |
| WO2026020127A2 (en) | 2024-07-19 | 2026-01-22 | Bristol-Myers Squibb Company | Methods of assessing citrullination and activity of pad2 modulators |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU570439B2 (en) | 1983-03-28 | 1988-03-17 | Compression Labs, Inc. | A combined intraframe and interframe transform coding system |
| SI0820279T1 (en) | 1995-04-14 | 2002-12-31 | Smithkline Beecham Corporation | Metered dose inhaler for albuterol |
| TW533865U (en) | 1997-06-10 | 2003-05-21 | Glaxo Group Ltd | Dispenser for dispensing medicament and actuation indicating device |
| HK1039325B (en) * | 1998-09-18 | 2006-02-24 | Abbott Gmbh & Co. Kg | 4-aminopyrrolopyrimidines as kinase inhibitors |
| US6315112B1 (en) | 1998-12-18 | 2001-11-13 | Smithkline Beecham Corporation | Method and package for storing a pressurized container containing a drug |
| US6390291B1 (en) | 1998-12-18 | 2002-05-21 | Smithkline Beecham Corporation | Method and package for storing a pressurized container containing a drug |
| US6119853A (en) | 1998-12-18 | 2000-09-19 | Glaxo Wellcome Inc. | Method and package for storing a pressurized container containing a drug |
| US6352152B1 (en) | 1998-12-18 | 2002-03-05 | Smithkline Beecham Corporation | Method and package for storing a pressurized container containing a drug |
| JP2003512353A (en) * | 1999-10-19 | 2003-04-02 | メルク エンド カムパニー インコーポレーテッド | Tyrosine kinase inhibitor |
| EP1990343B1 (en) | 1999-12-24 | 2012-04-04 | Aventis Pharma Limited | Azaindoles |
| GB0115393D0 (en) | 2001-06-23 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| WO2003000690A1 (en) | 2001-06-25 | 2003-01-03 | Aventis Pharmaceuticals Inc. | Synthesis of heterocyclic compounds employing microwave technology |
| CN1901958B (en) | 2003-11-03 | 2011-03-09 | 葛兰素集团有限公司 | Fluid distribution device |
| JP2007511596A (en) | 2003-11-17 | 2007-05-10 | ファイザー・プロダクツ・インク | Pyrrolopyrimidine compounds useful in the treatment of cancer |
| FR2862971B1 (en) * | 2003-11-28 | 2006-03-24 | Sod Conseils Rech Applic | NOVEL BENZIMIDAZOLE AND IMIDAZO-PYRIDINE DERIVATIVES AND THEIR USE AS A MEDICINAL PRODUCT |
| US7429611B2 (en) | 2004-09-23 | 2008-09-30 | Bristol-Myers Squibb Company | Indole inhibitors of 15-lipoxygenase |
| US20100197657A1 (en) | 2007-09-25 | 2010-08-05 | Chang Ronald K | 2-aryl or heteroaryl indole derivatives |
| WO2009155042A1 (en) | 2008-05-28 | 2009-12-23 | Wyeth | 3-substituted-1h-indole compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
| RU2011106786A (en) * | 2008-07-23 | 2012-08-27 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | PYRAZOLOPYRIDINKINASE INHIBITORS |
| SG174125A1 (en) * | 2009-04-02 | 2011-10-28 | Merck Serono Sa | Dihydroorotate dehydrogenase inhibitors |
| US20100305093A1 (en) | 2009-04-09 | 2010-12-02 | Exelixis, Inc. | Inhibitors of mTOR and Methods of Making and Using |
-
2012
- 2012-07-26 DK DK12740581.9T patent/DK2877467T3/en active
- 2012-07-26 SM SM20170052T patent/SMT201700052T1/en unknown
- 2012-07-26 PL PL12740581T patent/PL2877467T3/en unknown
- 2012-07-26 CN CN201280074868.5A patent/CN104470919B/en active Active
- 2012-07-26 ES ES12740581.9T patent/ES2609126T3/en active Active
- 2012-07-26 HR HRP20161530TT patent/HRP20161530T1/en unknown
- 2012-07-26 WO PCT/EP2012/064649 patent/WO2014015905A1/en not_active Ceased
- 2012-07-26 RU RU2014152456A patent/RU2611010C2/en active
- 2012-07-26 HU HUE12740581A patent/HUE033294T2/en unknown
- 2012-07-26 KR KR1020157005099A patent/KR101916443B1/en active Active
- 2012-07-26 CA CA2879341A patent/CA2879341C/en active Active
- 2012-07-26 AU AU2012386257A patent/AU2012386257B2/en active Active
- 2012-07-26 BR BR112015001545-0A patent/BR112015001545B1/en active IP Right Grant
- 2012-07-26 LT LTEP12740581.9T patent/LT2877467T/en unknown
- 2012-07-26 US US14/416,937 patent/US9127003B2/en active Active
- 2012-07-26 RS RS20170121A patent/RS55684B1/en unknown
- 2012-07-26 JP JP2015523426A patent/JP6063567B2/en active Active
- 2012-07-26 SI SI201230769A patent/SI2877467T1/en unknown
- 2012-07-26 IN IN2935KON2014 patent/IN2014KN02935A/en unknown
- 2012-07-26 PT PT127405819T patent/PT2877467T/en unknown
- 2012-07-26 EP EP12740581.9A patent/EP2877467B1/en active Active
-
2015
- 2015-08-03 US US14/816,246 patent/US9518054B2/en active Active
-
2016
- 2016-11-15 US US15/352,340 patent/US9833449B2/en active Active
-
2017
- 2017-01-24 SM SM201700052T patent/SMT201700052B/en unknown
- 2017-01-27 CY CY20171100128T patent/CY1118524T1/en unknown
- 2017-11-20 US US15/817,562 patent/US10039755B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1118524T1 (en) | 2- (AZAINDOL-2-MATERIAL) PETROL FILLING AS PAD4 SUSPENSIONS | |
| MX387321B (en) | BENZOIMIDAZOLE DERIVATIVES AS PEPTIDYL ARGININE DEIMINASE 4 (PAD4) INHIBITORS. | |
| MX2020003242A (en) | Heterocyclic compounds as pad inhibitors. | |
| PH12019501321A1 (en) | Methods of treating or preventing cholesterol related disorders | |
| GEP20207159B (en) | Diacylglycerol acyltransferase 2 inhibitors | |
| MX2020003341A (en) | Imidazo-pyridine compounds as pad inhibitors. | |
| CY1118656T1 (en) | PYRIDON PRODUCTION | |
| NZ736665A (en) | Heterocyclic amides as kinase inhibitors | |
| MX2015000129A (en) | Pyrimidine pyrazolyl derivatives. | |
| MX351471B (en) | Pyridinone and pyrimidinone derivatives as factor xia inhibitors. | |
| MX389105B (en) | INHIBITOR OF KINASES REARRANGED DURING TRANSFECTION (RET). | |
| NZ702070A (en) | Substituted pyrrolidines as factor xia inhibitors for the treatment thromboembolic diseases | |
| TN2015000245A1 (en) | Heterocyclic compound | |
| PH12014502788B1 (en) | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | |
| IL244392A0 (en) | Use of a composition comprising microorganisms to increase the intestinal production of butyric acid, folic acid or niacin and/or decrease the intestinal production of succinic acid | |
| MX2014002208A (en) | Serine/threonine pak1 inhibitors. | |
| MX2019000686A (en) | Diorganylphosphinic acid salts, method for the production thereof and the use thereof. | |
| WO2014144374A3 (en) | Process for pure carbon production, compositions, and methods thereof | |
| MY178390A (en) | Inhibitors of iap | |
| MX2017010624A (en) | Cyclic amine derivative and pharmaceutical use thereof. | |
| MX2017005423A (en) | Polyheteroaryl histone deacetylase inhibitors and their use in therapy. | |
| MX2016002718A (en) | KETO-IMIDAZOPYRIDINE DERIVATIVES AS RORc MODULATORS. | |
| MX2021015514A (en) | Heterocyclic compound. | |
| MX2017007577A (en) | Dihydropyrimidine-2-one compounds and medicinal uses thereof. | |
| MX369345B (en) | Processes for the preparation of oxytocin analogues. |